Navigation Links
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Date:12/10/2008

SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial tested the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in 32 healthy male volunteers. Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20 mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable.

"Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound."

About NU206

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, and bone disease.

About Nuvelo and Kyowa Hakko Kirin's Joint Collaborati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for ... The Innovation Center @3401 , a collaborative effort of ... to help attract and nurture start-up businesses in the ... , The Innovation Center @3401 (ic@3401), which is ... the new home of DreamIt Ventures and ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... Rice University,s award-winning undergraduate summer research program NanoJapan ... $4 million grant from the National Science Foundation ... from all U.S. universities, combines a traditional study-abroad ... internship in nanotechnology. The program was created in ...
... Sept. 21 Oxford Resource Partners, LP (NYSE: ... today announced their collaborative agreement to develop a pilot ... previously reclaimed from mining operations by Oxford. The goal ... economic viability of biomass production from dedicated energy crops ...
... JERUSALEM, Sept. 21 Chiasma, Inc., a privately ... CEO, will present an overview of the Company at the ... York, New York, on Wednesday, September 22, 2010 at 11:00 ... clinical trial of the investigational new drug Octreolin™, an oral ...
Cached Biology Technology:Rice University's award-winning NanoJapan program wins $4M grant 2Rice University's award-winning NanoJapan program wins $4M grant 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 2Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 4Chiasma to Present at the UBS Global Life Sciences Conference 2Chiasma to Present at the UBS Global Life Sciences Conference 3
(Date:7/29/2014)... bacteria and algae, propel themselves using whip-like appendages ... a millimetre long, function like tiny oars, helping ... cilia are found on the surfaces of many ... liquids over the cell. , Flagella and ... expel pathogens from our airways, they establish the ...
(Date:7/28/2014)... by the U.S. Food and Drug Administration (FDA) for ... bacterial pathogens inside human cells, including those that cause ... published in mBio , the online open-access journal ... way of identifying non-antibiotic drugs that could one day ... drugs on the list inhibit the growth of at ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ranging from the shellfish Swedish people eat at traditional ... their millions in both freshwater and saltwater. One of ... crustacean to have its genome sequenced. A researcher from ... The sequencing has been done in an international ...
... of cancer deaths resulted from metastasis, the spread of ... exploration of the possible mechanical factors that promote metastasis ... is expanding the scientific understanding of what makes malignant ... fibrous matrix that surrounds cancer cells. Karen ...
... SPRING HARBOR, N.Y. (March 22, 2011) - An ... to scientists and nonscientists alike. Its behavior involves processes ... those external to itenvironment and social surroundings. According to ... tapestry of biology: It is sparked when neurons fire ...
Cached Biology News:Surprising results in the first genome sequencing of a crustacean 2WSU proves extracellular matrix tugging creates come hither stimulus for cancer migration 2New book on animal behavior provides integrated view 2
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... moderate chemiluminescence efficiencies and the chemistry of ... the added benefit that they require simple ... background signal. This benefit has been exploited ... applications. These compounds can also be easily ...
... Deletion Kit for Kilo-Sequencing is designed to ... cloned into the multiple cloning sites (MCS) ... plasmid or phagemid vectors (pUC18/19). The kit ... in the target DNA, thereby progressively moving ...
Biology Products: